FerGene Appoints David Meek Chief Executive Officer
-FerGene, a new gene therapy company launched by Ferring Pharmaceuticals and Blackstone Life Sciences in November, today announced the appointment of David Meek as President and Chief Executive Officer …
FerGene announces pivotal Phase 3 study of nadofaragene firadenovec
-FerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, announced today positive results from the pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec …
Ferring and Blackstone Life Sciences invest over $570 million USD in novel gene therapy for bladder cancer patients
-Ferring and Blackstone Life Sciences invest over $570 million USD in novel…
Heat-stable carbetocin has been added to the WHO Essential Medicines List for the prevention of excessive bleeding after childbirth
-Ferring Pharmaceuticalstoday welcomes the World Health Organization’s (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML)…
Ferring announces changes to Executive Committee
-Ferring Pharmaceuticals announced today that Lars Peter Brunse is retiring from his role as Executive Vice President and Chief Production Officer. Armin Metzger, previously Senior Vice President, Head of Global Pharmaceutical R&D, has been appointed
Archives Press release 2019
Archives Press release 2019